Clinical Trials on Essential Thrombocythaemia Myelofibrosis in Finland

Total 24 results

Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
Incyte Corporation

Recruiting

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)

Myelofibrosis | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome | Relapsed or Refractory Primary Myelofibrosis | Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis) | ET...

United States, Spain, Japan, Italy, Finland, United Kingdom, Canada
Incyte Corporation

Completed

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

MPN (Myeloproliferative Neoplasms)

United States, Puerto Rico
Shire

Completed

Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments

Thrombocythemia, Essential

Spain, United Kingdom, Greece, Denmark, Italy, France, Finland, Norway, Sweden, Germany, Cyprus, Ireland, Netherlands, Portugal
Helsinki University Central Hospital

Completed

A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension (GENRES)

Hypertension | Pharmacogenetics

Finland
Actuate Therapeutics Inc.

Completed

Actuate 1901: 9-ING-41 in Myelofibrosis

Myelofibrosis

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Finland, Norway, Sweden, France, Germany, Italy, Turkey, Argentina, Chile, Ecuador, Spain, Switzerland
Tampere University
Finnish Cultural Foundation; Sigrid Jusélius Foundation; Päivikki and Sakari... and other collaborators

Recruiting

HaemoDYNAMICs in Primary and Secondary Hypertension (DYNAMIC)

Renal Insufficiency | Aortic Stenosis | Primary Hypertension | Secondary Hypertension

Finland
Novartis Pharmaceuticals

Completed

Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension

Hypertension

Czech Republic, Finland, France, Germany, Hungary, Italy, Poland, Slovakia, Spain, Sweden
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Novartis Pharmaceuticals

Completed

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension (ALLAY)

Hypertension | Overweight | Left Ventricular Hypertrophy

United States, Finland, Sweden, Germany, Italy, Spain, Argentina, Colombia, Russian Federation
Takeda

Completed

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Hypertension

Poland, Germany, Bulgaria, Russian Federation, Serbia, Sweden, Netherlands, Estonia, Slovakia, Finland
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

Hypertension

United States
Celgene

Recruiting

Connect® Myeloid Disease Registry

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Primary Myelofibrosis

United States, Puerto Rico
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Hypertension

United States
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Chile, Mexico
Theracos

Completed

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

Essential Hypertension

United States
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Essential Hypertension

United States, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Hypertension

Spain, Italy, Netherlands, United States, Denmark, Taiwan, Argentina, Germany, Russian Federation, Slovakia, Canada, Hungary, Latvia, Lithuania, Poland, Finland, France, Sweden
Cala Health, Inc.

Completed

Prospective Study for Symptomatic Relief of ET With Cala Therapy (PROSPECT)

Essential Tremor

United States
Jazz Pharmaceuticals

Active, not recruiting

A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

Essential Tremor

United States, Spain, Poland, Germany
NicOx

Completed

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension (HCT3012-X-112)

Hypertension | Osteoarthritis

United States
Abbott Medical Devices

Recruiting

Abbott DBS Post-Market Study of Outcomes for Indications Over Time (ADROIT)

Parkinson Disease | Movement Disorders | Dystonia | Essential Tremor | Tremor | Primary Dystonia | Secondary Dystonia

United States, Australia, Spain, United Kingdom, Finland, France, Germany, Italy, Taiwan

Clinical Trials on Essential Thrombocythaemia Myelofibrosis in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations